Literature DB >> 26211419

Safety, immunization coverage and determinants of a new kind of Hepatitis B vaccine firstly applied in Ningbo, China.

Sijia Yang1, Xiao Ma1, Hongxia Ni1, Shaoying Zhou1, Danbiao Hu2, Honghui Shi3, Xiaoying Chen1, Hongjun Dong1, Guozhang Xu1.   

Abstract

Evaluate safety and immunization coverage of a new kind of recombinant Hepatitis B vaccine (HepB) in Ningbo city, China. Two groups were carried out in 2 of 11 randomly selected countries in Ningbo in 2009. All of the infants born from July 1 to December 31, 2009 were enrolled as subjects and received 3 doses of HepB at 0, 1, 6 month. Control group (N = 3452) received current HepB derived from Saccharomyces Cerevisiae Yeast (HepB made by recombinant DNA techniques in Saccharomyces Cerevisiae Yeast, HepB-SCY; 5 μg/0.5 ml per dose) and experimental group (N = 5104) received the new kind of HepB derived from Hansenula polymorpha Yeast (HepB made by recombinant DNA techniques in Hansenula polymorpha Yeast, HepB-HPY; 10 μg/0.5 ml per dose). 3-dose and timely birth dose (TBD) coverage were available and compared between 2 groups. Standard structured questionnaires were applied to record information from parents and hospitals for selecting determinants of coverage. The data were analyzed using stepwise multiple logistic regression models. After each dose, HepB-related adverse events (AEs) and recta-temperature were recorded for 7 days. 3-dose coverage in control group (89.98%) was higher than that in experimental group (χ2 = 575.1173, P < 0.0001). TBD coverage in control and experimental group were 98.41% and 98.53%, respectively. No statistically significant difference in TBD coverage was found between 2 groups (χ2 = 0.0623, P = 0.8029). A total of 9 local AEs were reported, 4 for control group and 5 for experimental group. The percentages of subjects reporting AEs were similar across the 2 vaccination groups. No serious or immediate reactions were found in this study. From logistic models, receiving 10 μg vaccine (odds ratio [OR]:0.38; 95% confidence interval [95%CI]: 0.34-0.44) and mother migrating from other cities (OR: 0.45; 95%CI: 0.42-0.47) were the determinants for non-acceptance of 3 doses of HepB; infants born from low grade hospitals and native mothers contributed to administrate the TBD.

Entities:  

Keywords:  coverage; determinants; hepatitis b vaccine; infants; safety

Mesh:

Substances:

Year:  2015        PMID: 26211419      PMCID: PMC4916460          DOI: 10.1080/21645515.2015.1066946

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  33 in total

Review 1.  Hepatitis B virus infection--natural history and clinical consequences.

Authors:  Don Ganem; Alfred M Prince
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

2.  Vertical transmission of hepatitis B antigen in Taiwan.

Authors:  C E Stevens; R P Beasley; J Tsui; W C Lee
Journal:  N Engl J Med       Date:  1975-04-10       Impact factor: 91.245

Review 3.  Hepatitis B virus infection.

Authors:  Christian Trépo; Henry L Y Chan; Anna Lok
Journal:  Lancet       Date:  2014-06-18       Impact factor: 79.321

4.  Age at time of hepatitis Be antibody seroconversion in childhood chronic hepatitis B infection and mutant viral strain detection rates.

Authors:  T Ando; K Sugiyama; K Goto; Y Miyake; R Li; Y Kawabe; Y Wada
Journal:  J Pediatr Gastroenterol Nutr       Date:  1999-11       Impact factor: 2.839

Review 5.  Update on epidemiology of hepatitis B and C in China.

Authors:  Yan Cui; Jidong Jia
Journal:  J Gastroenterol Hepatol       Date:  2013-08       Impact factor: 4.029

6.  Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.

Authors:  Hui-Fang Hung; Tony Hsiu-Hsi Chen
Journal:  Vaccine       Date:  2009-09-05       Impact factor: 3.641

Review 7.  Global control of hepatitis B virus infection.

Authors:  Jia-Horng Kao; Ding-Shinn Chen
Journal:  Lancet Infect Dis       Date:  2002-07       Impact factor: 25.071

8.  Evolution of hepatitis B vaccine coverage rates in France between 2008 and 2011.

Authors:  F Denis; R Cohen; A Martinot; J-P Stahl; T Lery; M Le Danvic; J Gaudelus
Journal:  Med Mal Infect       Date:  2013-07-19       Impact factor: 2.152

Review 9.  Risks of chronicity following acute hepatitis B virus infection: a review.

Authors:  K C Hyams
Journal:  Clin Infect Dis       Date:  1995-04       Impact factor: 9.079

10.  Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination.

Authors:  Xiaofeng Liang; Shengli Bi; Weizhong Yang; Longde Wang; Gang Cui; Fuqiang Cui; Yong Zhang; Jianhua Liu; Xiaohong Gong; Yuansheng Chen; Fuzhen Wang; Hui Zheng; Feng Wang; Jing Guo; Zhiyuan Jia; Jingchen Ma; Huaqing Wang; Huiming Luo; Li Li; Shuigao Jin; Stephen C Hadler; Yu Wang
Journal:  Vaccine       Date:  2009-09-01       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.